JP2023547728A - 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物 - Google Patents

間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物 Download PDF

Info

Publication number
JP2023547728A
JP2023547728A JP2023527970A JP2023527970A JP2023547728A JP 2023547728 A JP2023547728 A JP 2023547728A JP 2023527970 A JP2023527970 A JP 2023527970A JP 2023527970 A JP2023527970 A JP 2023527970A JP 2023547728 A JP2023547728 A JP 2023547728A
Authority
JP
Japan
Prior art keywords
aat
pharmaceutical composition
mscs
extracellular vesicles
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547728A5 (https=
Inventor
シュタングル，マンフレート
ストラスメア，マイケル
Original Assignee
アーテック メディカル ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20206287.3A external-priority patent/EP3995130A1/en
Application filed by アーテック メディカル ジーエムビーエイチ filed Critical アーテック メディカル ジーエムビーエイチ
Publication of JP2023547728A publication Critical patent/JP2023547728A/ja
Publication of JP2023547728A5 publication Critical patent/JP2023547728A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023527970A 2020-11-06 2021-11-08 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物 Pending JP2023547728A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20206287.3 2020-11-06
EP20206287.3A EP3995130A1 (en) 2020-11-06 2020-11-06 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP21159620 2021-02-26
EP21159620.0 2021-02-26
PCT/EP2021/080936 WO2022096708A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2023547728A true JP2023547728A (ja) 2023-11-13
JP2023547728A5 JP2023547728A5 (https=) 2024-11-12

Family

ID=78806458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527970A Pending JP2023547728A (ja) 2020-11-06 2021-11-08 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物

Country Status (7)

Country Link
US (1) US20230414730A1 (https=)
EP (1) EP4240323A1 (https=)
JP (1) JP2023547728A (https=)
AU (1) AU2021375735A1 (https=)
CA (1) CA3200691A1 (https=)
IL (1) IL302649A (https=)
WO (1) WO2022096708A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN115381857B (zh) * 2022-10-28 2023-02-03 上海市东方医院（同济大学附属东方医院） 间充质干细胞在制备治疗hpv持续感染的药物中的应用
EP4680254A1 (en) * 2023-03-17 2026-01-21 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025227013A1 (en) * 2024-04-26 2025-10-30 Musc Foundation For Research Development Extracellular vesicles from alpha-1 antitrypsin overexpressing cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505656A (ja) * 1992-09-30 1995-06-22 ジョン　レズディ 抗ウイルス剤
JP2009297031A (ja) * 2000-12-18 2009-12-24 Arriva Pharmaceuticals Inc 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
JP2010524971A (ja) * 2007-04-20 2010-07-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン
JP2018502579A (ja) * 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539099C2 (ru) 2009-04-13 2015-01-10 Апцет Гмбх Унд Ко.Кг Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
US9901600B2 (en) * 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505656A (ja) * 1992-09-30 1995-06-22 ジョン　レズディ 抗ウイルス剤
JP2009297031A (ja) * 2000-12-18 2009-12-24 Arriva Pharmaceuticals Inc 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
JP2010524971A (ja) * 2007-04-20 2010-07-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン
JP2018502579A (ja) * 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIORXIV [PREPRINT], vol. 2023 May 8, JPN6025034807, 15 August 2020 (2020-08-15), pages 248880, ISSN: 0005670474 *

Also Published As

Publication number Publication date
AU2021375735A9 (en) 2024-09-05
CA3200691A1 (en) 2022-05-12
US20230414730A1 (en) 2023-12-28
EP4240323A1 (en) 2023-09-13
AU2021375735A1 (en) 2023-06-08
IL302649A (en) 2023-07-01
WO2022096708A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
JP2023547728A (ja) 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
WO2019046664A1 (en) COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS
TW202334430A (zh) 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染
FR2711523A1 (fr) Procédé de préparation d'un aérosol viral.
US20230144927A1 (en) Methods for the treatment of viral respiratory infections
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
US20210189427A1 (en) Compositions and methods for gene delivery to the airways and/or lungs
US20210087245A1 (en) Compositions and methods for delivering cftr polypeptides
EP3995130A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US20260000791A1 (en) In vivo gene therapy using intraosseous delivery of a lentiviral gene construct
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
AU732447B2 (en) Gene delivery and expression in areas inaccessible to direct protein delivery
RS55154B1 (sr) Interferon beta za upotrebu u lečenju bolesti donjeg respiratornog trakta uzrokovane gripom
RU2770364C1 (ru) Способ лечения болезней легких ингаляционным введением мезенхимальных стромальных клеток и гексапептида
Fröhlich Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases—Intravenous Administration versus Inhalation. Pharmaceutics 2021, 13, 232
CN118434880A (zh) 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途
CN102369012A (zh) 氧化氘用于治疗病毒性呼吸道疾病的用途
Popowski et al. Arianna George4, 5, Halle Lutz1, 2, Jada Davenport5, Asma Ghodsi1, Moriah Zarzar1, Mengrui Liu1, 3, Phuong-Uyen C. Dinh1, 2, Ke Cheng1, 2, 3, 8

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20230619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260316